Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.79 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624174 | 0.88 | KIF11 (1.00) | KIF11CASP3KCNH2MAOBNT5E | |
| SCHEMBL3626735 | 0.85 | KIF11 (1.00) | KIF11CASP3KCNH2MAOBNT5E | |
| SCHEMBL3616992 | 0.84 | KIF11 (0.72) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3614716 | 0.84 | KIF11 (0.72) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3620275 | 0.82 | KIF11 (0.79) | KIF11CASP3KCNH2MAOAMAOB | |
| SCHEMBL13618594 | 0.82 | KIF11 (0.66) | KIF11CASP3KCNH2MAOAMAOB | |
| SCHEMBL3620833 | 0.82 | KIF11 (0.69) | KIF11CASP3KCNH2MAOBNT5E | |
| SCHEMBL3618256 | 0.82 | KIF11 (0.69) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3624129 | 0.81 | KIF11 (0.68) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL28205856 | 0.79 | MEN1 (0.74) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745639-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-29 | — | — | US | claimed |
| EP-1492487-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | claimed |
| EP-1492487-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003079973-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-10-02 | — | — | WO | claimed |
| US-7745639-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119484-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF23 | KIF11 8/4885CASP3 2677/4885KCNH2 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.